Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H56:IC31 and Etoricoxib in Tuberculosis
NCT02503839Phase 1Completed
- Start
- Nov 2015
- Primary completion
- Sep 2019
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AERAS-456 and etoricoxib in Tuberculosis (TB) (4 arms). Primary endpoints: Safety of etoricoxib assessed by adverse events, Safety of H56:IC31 vaccine assessed by adverse events and 4 more. Started Nov 2015; status: completed.
02
Drugs
AERAS-456etoricoxib
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02503839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02503839.